Relative contribution of risk factors/co-morbidities to heart failure pathogenesis: interaction with ejection fraction

被引:5
|
作者
Giamouzis, Grigorios [1 ]
Xanthopoulos, Andrew [1 ]
Papamichalis, Michail [1 ]
Chroub-Papavaiou, Artemis-Nantia [1 ,2 ]
Pantziou, Aikaterini [1 ,3 ]
Simou, Anthi [1 ]
Dimos, Apostolos [1 ]
Bourazana, Angeliki [1 ]
Skoularigis, John [1 ]
Triposkiadis, Filippos [1 ]
机构
[1] Gen Univ Hosp Larissa, Dept Cardiol, POB 1425, Larisa 41110, Greece
[2] Papageorgiou Gen Univ Hosp, Thessaloniki, Greece
[3] Gen Hosp Volos, Dept Cardiol, Volos, Greece
来源
ESC HEART FAILURE | 2020年 / 7卷 / 06期
关键词
Heart Failure; Morbidity; Co-morbidity; Coexisting disease; Hypertension; Myocardial infarction; Atrial fibrillation; Ejection fraction; NONCARDIAC COMORBIDITIES; CO-MORBIDITIES;
D O I
10.1002/ehf2.12975
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims The relative impact of each individual coexisting morbidity on the pathogenesis of heart failure (HF) is incompletely understood. This study aimed to evaluate the prevalence of individual cardiac and non-cardiac coexisting morbidities both in the overall HF population and in the subgroup of HF patients with a single coexisting morbidity, stratified by left ventricular ejection fraction (LVEF) categories, as a measure of the relative contribution of each co-morbidity to the pathogenesis of HF. Methods and results This is a prospective, observational study, in which unselected ambulatory patients with chronic HF visiting the HF clinic of a tertiary university hospital from January 2016 to January 2019 were classified according to baseline LVEF into three groups: (i) LVEF < 40%, (ii) LVEF = 40-49%, and (iii) LVEF >= 50% and then evaluated for various coexisting morbidities. Overall, 1064 patients (age 73.4 +/- 12.1 years, male gender 57.7%, LVEF 43.6 +/- 13.9, N-terminal pro-brain natriuretic peptide 2187 +/- 710 ng/L, and estimated glomerular filtration rate 67.2 +/- 25 mL/min/1.73 m(2)) were recruited in this study. Of these, 361 (33.9%) had an LVEF < 40%, 247 (23.2%) an LVEF = 40-49%, and 456 (42.9%) an LVEF >= 50%. There were 90 (8.5%) HF patients with a single coexisting morbidity, 33 (36.7%) with LVEF >= 50%, 27 (30.0%) with LVEF = 40-49%, and 30 (33.3%) with LVEF < 40%. Among these patients, those with LVEF >= 50% suffered mostly from hypertension (85.7%), whereas the second most common coexisting morbidity was atrial fibrillation (AF) (9.5%). HF patients with LVEF = 40-49% usually suffered from hypertension (35.7%), AF (28.6%), or myocardial infarction (MI) (21.4%). Finally, HF patients with LVEF < 40% usually suffered from MI (30.8%), AF (30.8%), or hypertension (15.4%). Conclusions Hypertension is strongly associated with the development of HF with low, intermediate, or near-normal/normal LVEF whereas a history of MI or AF with HF with a low or an intermediate LVEF.
引用
收藏
页码:4399 / 4403
页数:5
相关论文
共 50 条
  • [11] The effect of three major co-morbidities on quality of life and outcome of patients with heart failure with reduced ejection fraction
    Benes, Jan
    Kotrc, Martin
    Jarolim, Petr
    Hoskova, Lenka
    Hegarova, Marketa
    Dorazilova, Zora
    Podzimkova, Mariana
    Binova, Jana
    Lukasova, Marianna
    Malek, Ivan
    Franekova, Janka
    Jabor, Antonin
    Kautzner, Josef
    Melenovsky, Vojtech
    ESC HEART FAILURE, 2021, 8 (02): : 1417 - 1426
  • [12] Improvement In Metabolic Co-morbidities After Implantation of Cardiomems In Patients with Heart Failure with Preserved Ejection Fraction Phenotype
    Alam, Amit
    Nayyar, Navdeep
    Weber, Jonathan Jonathan
    Hall, Shelley A.
    Jermyn, Rita
    JOURNAL OF CARDIAC FAILURE, 2020, 26 (10) : S124 - S124
  • [13] A review of patients with Heart Failure with mid-range Ejection Fraction (HFmrEF): co-morbidities and outcomes.
    O'Callaghan, D. Daniel
    Wheen, P.
    Murray, P.
    Minelli, C.
    Shiels, P.
    Maher, V.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 350 - 350
  • [14] Improvement in Metabolic Co-Morbidities after Implantation of CardioMEMS in Patients with Heart Failure with Preserved Ejection Fraction Phenotype
    Alam, Amit
    Van Zyl, Johanna
    Nayyar, Navdeep
    Hall, Shelley
    Jermyn, Rita
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (19)
  • [15] Coexisting Morbidities in Heart Failure: No Robust Interaction with the Left Ventricular Ejection Fraction
    Xanthopoulos, Andrew
    Dimos, Apostolos
    Giamouzis, Grigorios
    Bourazana, Angeliki
    Zagouras, Alexandros
    Papamichalis, Michail
    Kitai, Takeshi
    Skoularigis, John
    Triposkiadis, Filippos
    CURRENT HEART FAILURE REPORTS, 2020, 17 (04) : 133 - 144
  • [16] Coexisting Morbidities in Heart Failure: No Robust Interaction with the Left Ventricular Ejection Fraction
    Andrew Xanthopoulos
    Apostolos Dimos
    Grigorios Giamouzis
    Angeliki Bourazana
    Alexandros Zagouras
    Michail Papamichalis
    Takeshi Kitai
    John Skoularigis
    Filippos Triposkiadis
    Current Heart Failure Reports, 2020, 17 : 133 - 144
  • [17] Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction
    Lund, Lars H.
    Donal, Erwan
    Oger, Emmanuel
    Hage, Camilla
    Persson, Hans
    Haugen-Lofman, Ida
    Ennezat, Pierre-Vladimir
    Sportouch-Dukhan, Catherine
    Drouet, Elodie
    Daubert, Jean-Claude
    Linde, Cecilia
    EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 (09) : 992 - 1001
  • [18] Heart failure: focus on co-morbidities, inflammation, and heart rate
    Luescher, Thomas F.
    EUROPEAN HEART JOURNAL, 2015, 36 (11) : 635 - 637
  • [19] Cancer and heart failure-more than meets the eye: common risk factors and co-morbidities
    Anker, Markus S.
    von Haehling, Stephan
    Landmesser, Ulf
    Coats, Andrew J. S.
    Anker, Stefan D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 (10) : 1382 - 1384
  • [20] Reframing the association and significance of co-morbidities in heart failure
    Triposkiadis, Filippos
    Giamouzis, Gregory
    Parissis, John
    Starling, Randall C.
    Boudoulas, Harisios
    Skoularigis, John
    Butler, Javed
    Filippatos, Gerasimos
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 (07) : 744 - 758